Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants. (Q50217903)

27 February 2018

title

Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants. (English)

1 reference

27 February 2018

author name string

Schaad UB

1

1 reference

27 February 2018

McCracken GH Jr

2

1 reference

27 February 2018

Threlkeld N

3

1 reference

27 February 2018

Thomas ML

4

1 reference

27 February 2018

language of work or name

English

0 references

publication date

1 January 1981

1 reference

27 February 2018

The Journal of Pediatrics

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

27 February 2018

volume

98

1 reference

27 February 2018

issue

1

1 reference

27 February 2018

page(s)

129-136

1 reference

27 February 2018

A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

In vitro activity of LY127935.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

Comparative Activities of the Oxa-β-Lactam LY127935, Cefotaxime, Cefoperazone, Cefamandole, and Ticarcillin Against Multiply Resistant Gram-Negative Bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

The two-compartment open-system kinetic model: A review of its clinical implications and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

Drug therapy. Clinical Pharmacokinetics (first of two parts).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

Clinical pharmacokinetics (second of two parts).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2881%2980559-8

10.1016/S0022-3476(81)80559-8

7 January 2021

Identifiers

DOI

1 reference

27 February 2018

1 reference

27 February 2018